Syndax Pharmaceuticals Inc

SNDXNASDAQ · USD
17.90USD+0.26 (+1.48%)
127

Syndax Pharmaceuticals Inc (SNDX) Wheel Strategy

SNDX wheel strategy scan found 11 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 79.1%.

Read more

Running a SNDX wheel strategy lets you generate consistent premium income on Syndax Pharmaceuticals Inc while setting your own entry and exit prices on the underlying. Syndax Pharmaceuticals Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own SNDX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best SNDX wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on SNDX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable SNDX wheel from a losing one.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat.

It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the SNDX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your SNDX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Nov 20, 202615.00$0.70$1.95-0.266023%72.3%79.1%2
Oct 16, 202617.00$0.45$0.70-0.322523%61.3%60.1%141
Nov 20, 202617.00$1.25$1.68-0.366023%54.8%59.9%18
Nov 20, 202616.00$0.90$1.18-0.286023%63.7%44.7%10
Jan 15, 202717.00$1.90$2.35-0.3511623%50.6%43.5%27
Jan 15, 202716.00$1.10$1.65-0.3011623%57.1%32.4%10
Jan 15, 202715.00$1.15$1.43-0.2511623%63.8%29.9%74
Apr 16, 202716.00$0.55$2.63-0.3020723%51.8%28.9%1
Jan 15, 202714.00$0.75$1.18-0.2111623%70.5%26.4%45
Jan 21, 202813.00$1.55$3.28-0.1948723%54.9%18.9%80

As of September 23, 2026

Run the Wheel on SNDX With Confidence

Find the best SNDX wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial